NCT06400264 2024-05-06
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT05161533 2023-10-18
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
Phase 2 Withdrawn
NCT04262869 2021-10-27
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Emory University
Phase 2 Withdrawn
NCT03935347 2020-01-02
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT03644589 2019-04-26
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
University of Washington
Phase 2 Withdrawn
NCT03402880 2018-10-10
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT02966587 2018-01-17
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
Phase 2 Withdrawn